Merck Sante
Records under this name other than patents Merck Sante holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Merck Sante
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,034,021 | Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses Term ended Term ended Oct 31, 2021 · From the USPTO record | Term ended | Term ended Oct 31, 2021 | From the USPTO record |
| US 7,767,676 | Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses Term ended Term ended Oct 25, 2021 · From the USPTO record | Term ended | Term ended Oct 25, 2021 | From the USPTO record |
| US 7,452,883 | Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses Term ended Ended no later than Jan 25, 2021 · From the USPTO record | Term ended | Ended no later than Jan 25, 2021 | From the USPTO record |
| US 6,512,009 | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator Term ended Term ended Jan 12, 2021 · From the USPTO record | Term ended | Term ended Jan 12, 2021 | From the USPTO record |
| US 6,265,437 | Aminoalkanesulphonic acid derivatives, their preparation and their use as medicaments Term ended Term ended Oct 12, 2020 · From the USPTO record | Term ended | Term ended Oct 12, 2020 | From the USPTO record |
| US RE38,629 | Solid oral dosage form comprising a combination of metformin and glibenclamide Term ended Term ended Jul 14, 2019 · From the USPTO record | Term ended | Term ended Jul 14, 2019 | From the USPTO record |
| US 7,651,844 | Method for screening agents capable of treating obesity Lapsed on the fee record Ended Jan 26, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 26, 2018 | From the USPTO record |
| US 8,119,609 | Methods of treating diabetic retinopathy with pericyte apoptosis inhibitors Lapsed on the fee record Ended Feb 21, 2016 · From the USPTO record | Lapsed on the fee record | Ended Feb 21, 2016 | From the USPTO record |
| US 6,303,146 | Solid oral dosage form comprising a combination of metformin and glibenclamide Formerly held Surrendered on reissue Surrendered on reissue Oct 19, 2004 · From the USPTO record | Surrendered on reissue | Surrendered on reissue Oct 19, 2004 | From the USPTO record |
| US 5,769,073 | Powder inhalator Formerly held Term ended Term ended no later than Jun 23, 2018 · Low confidence | Term ended | Term ended no later than Jun 23, 2018 | Low confidence |